Pfizer to Acquire Arena Pharmaceuticals
December 14, 2021
Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena. The boards of directors of both companies have unanimously approved the transaction.
The proposed acquisition allows Arena to utilize Pfizer’s established infrastructure across global markets and expertise in Inflammation and Immunology, as well as Cardiology, to accelerate and advance Arena’s pipeline. Arena believes this transaction represents the best next step for the company and will potentially allow them to more rapidly address unmet needs for a broader number of patients with inflammatory and cardiovascular diseases.
The proposed transaction is subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena stockholders. Arena is committed to executing a smooth transition. Between now and the closing date, operations at Arena will not change. Arena will continue to enroll studies and drive forward on our stated timelines.
Read the press release with transaction information here »
Recent News
- Collaboration with Quest Diagnostics to expand kidneyintelX.dkd TM testing in the United States
- Utah Business Innovation Awards Summit Recap
- Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
- Co-Diagnostics Expands Vector Smart® Customer Reach with First International Installation in USAF Base
- Rep. Celeste Maloy Tours BIOS, Neurotech Innovation
- U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam for Pediatric Patients with Tourette Syndrome
